Supply of NovaSeq X Series 25B Reagent Kits

The contract entails the procurement and delivery of proprietary NovaSeq X Series 25B Reagent Kits designed for high-throughput DNA sequencing on Illumina platforms, specifically to advance research into neurodegenerative diseases. These reagent kits are critical for enabling large-scale genomic analysis required for identifying disease biomarkers, understanding genetic variations, and developing targeted therapeutic strategies. The order is structured as a subcontract under the auspices of the National Institutes of Health, operating through the Department of Health and Human Services, with performance to be completed at a facility in Bethesda, Maryland, zip code 20892. The reagents are proprietary and must meet exact technical specifications to ensure compatibility and optimal performance with existing Illumina sequencing systems in use at the research site. The solicitation was posted on April 27, 2026, with a firm response deadline of May 7, 2026, at 10:00 AM, indicating a tight turnaround for potential suppliers to submit proposals. The North American Industry Classification System code 325414 identifies the nature of the procurement as related to biological product manufacturing, underscoring the technical and regulatory rigor expected in supplying these reagents. No set-aside provisions are specified, suggesting the opportunity is open to all eligible vendors without restrictions based on business size or status. Delivery must align with strict quality control timelines and logistical requirements to avoid disruptions in ongoing research efforts, with the integrity and consistency of the reagent kits directly impacting the validity of experimental results in high-stakes neuroscience studies.